HDL function and mortality in end stage renal disease

描述（由申请人提供）： 大约9%的美国人口患有慢性肾脏疾病，尽管退伍军人中的患病率甚至更高，因为该患者人群中糖尿病和高血压（CKD的根本原因）的患病率很高。在这个惊人的数字中，大约有45万名患者患有终末期肾病（ESRD），需要维持透析。预计到2020年，ESRD患者人数将增加到70万人。透析患者的五年生存率约为35%，比许多癌症更差。这些死亡中有一半归因于心血管疾病（CVD）。因此，旨在发现可以识别CVD高风险患者的新途径/分子的研究至关重要。此外，可以探索这些途径以确定潜在的治疗靶点。鉴于HDL在预防和逆转CVD中的关键作用，旨在评估和改善ESRD患者HDL功能的研究具有相当大的临床和治疗价值。

DESCRIPTION (provided by applicant): Approximately 9% of the United States population have chronic kidney disease, although, this prevalence is even higher in Veterans given the high prevalence of diabetes and hypertension (underlying causes of CKD) in this patient population. Out of this staggering number, approximately 450,000 patients have end stage renal disease (ESRD) requiring maintenance dialysis. The number of patients with ESRD is expected to increase to 700,000 by 2020. Five year survival for patients on dialysis is about 35%, a rate worse than many cancers. Half of these deaths are attributed to cardiovascular disease (CVD). Therefore, investigations aimed at discovering novel pathways/molecules that can identify patients at high risk for CVD are of vital importance. Furthermore, these pathways can be explored to identify potential targets for therapy. Given the critical role HDL plays in prevention and reversal of CVD, studies aimed at evaluating and improving HDL function in ESRD patients are of considerable clinical and therapeutic value.